Pinealon

Overview

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR). It comes from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and belongs to the family of "short peptide bioregulators" / "cytogens" promoted by that group. It is marketed and discussed with a nootropic and neuroprotective framing.

The chemistry is well defined: PubChem lists it under CID 10273502 with molecular formula C15H26N6O8 and molecular weight ~418.4 g/mol, and chemical suppliers report the CAS number 175175-23-2. The biology, by contrast, is where caution is required. The proposed mechanism — that this very small peptide enters the cell nucleus and binds specific DNA sequences to steer transcription of neuroprotective and antioxidant genes — is supported mainly by in-vitro and animal work, and the human evidence is limited, older, largely Russian-language, single-group, and independently unconfirmed.

Pinealon is often grouped with other compounds from the same school, such as Epitalon, and with other nootropic neuropeptides such as Selank and Semax. As with those compounds, the central thing to understand is the gap between confident mechanistic claims and thin, non-independent human evidence. It is not an approved medicine anywhere.

Chemistry and structure

Pinealon is a linear tripeptide (three amino acids):

Glu-Asp-Arg (one-letter code: EDR)

The molecule carries two acidic residues (Glu, Asp) and one basic residue (Arg). Note the CAS number is consistently reported by chemical suppliers (MedChemExpress, BOC Sciences) but was not confirmed on the PubChem record retrieved, so it is reported here rather than treated as fully authoritative.

Mechanism of action

The mechanisms below are best read as proposed pathways, most of them from a single research school and grounded in cell and animal models rather than controlled human pharmacology. Each claim is tagged with its evidence level.

• Nuclear penetration and DNA binding. The small tripeptide is reported to penetrate the cell cytoplasm and nucleus — fluorescently-labelled EDR was tracked into the nucleus within minutes — and to bind specific promoter DNA sequences (e.g. d(CCTGCC)₂, d(CCAGC)₂) to regulate gene expression and protein synthesis. [In vitro / Hypothesis] (Molecules, 2021 — PMC7795577)
• Upregulation of antioxidant genes. EDR is reported to increase expression of the antioxidant enzyme genes SOD2 and GPX1 and of serotonin-pathway TPH1, and to raise PPARA/PPARG expression. [In vitro] (PMC7795577)
• Anti-apoptotic / anti-oxidative shift. EDR is reported to reduce pro-apoptotic caspase-3 and p53, lower reactive oxygen species, and modify ERK1/2 MAPK signalling timing in neurons under oxidative / hyperhomocysteinemia stress. [In vitro / Animal] (PMC7795577)
• Structural / cognitive effects in disease models. EDR is reported to restore dendritic spine density and improve Morris water-maze learning in Alzheimer-model rodents. [Animal] (PMC7795577)

Research and evidence

The evidence base is preclinical-heavy, older, and dominated by the originating Khavinson group, with no independent replication located.

Human evidence. There are no well-established, independent human clinical trials of Pinealon. The reported human data are limited, older, and essentially from the originating St. Petersburg group. A 2021 review states that EDR peptide has been examined in "elderly patients with cognitive impairment and consequences of traumatic brain injury" with reported memory/cognitive improvement [Human], but the primary trials are small, not blinded by modern standards, largely Russian-language, and not confirmed by any registered independent RCT. No FDA/EMA clinical-efficacy evaluation exists. No primary trial citations (author, year, journal, sample size, design) were retrieved beyond that review's summary, so human efficacy should be treated as unproven at the primary-trial level.

Status and regulation

Pinealon is not FDA- or EMA-approved for any indication. No published FDA/EMA evaluation, label, or marketing authorisation was found. It is distributed as "research use only" material by chemical/peptide vendors.

As with any unapproved peptide, it becomes an unauthorised medicinal product the moment it is intended for human use; "no specific ban found" is not affirmative permission.

WADA status: Not established. No primary WADA source lists Pinealon. Vendor or blog claims that it is "prohibited under S0" are inference from its non-approved status, not a WADA assertion, and are not recorded here as sourced. Athletes subject to anti-doping rules should consult current WADA guidance directly rather than assume a classification.

Safety

• There is no FDA/EMA document, label, or toxicology dossier for Pinealon, so its human safety profile is not established in primary regulatory sources.
• A lack of reported adverse events reflects a lack of rigorous study, not a demonstration of safety.
• Material sold as "Pinealon" is a research reagent; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• Because it is used as an injectable peptide in research and unregulated contexts, the usual risks of non-sterile injectable products also apply.

Legal status

Pinealon is best described by its regulatory classification, not by any notion of "legal for human use." It is sold as a research reagent / "research use only" chemical and is not approved by the FDA or EMA. No specific prohibition was found in the sources consulted — but "no specific ban" is not affirmative permission, and the compound becomes an unauthorised medicinal product the moment it is intended for human use. Legality and WADA sport-eligibility are separate axes; neither implies the other.

This is not legal advice, and legal status varies by country and changes over time. Check the rules in your own jurisdiction. Status current as of the July 2026 research date.

How it compares

• Epitalon — another ultra-short peptide from the same Khavinson bioregulator school, framed around anti-aging/telomeres. It shares Pinealon's central caveat: bold mechanistic claims resting on older, mostly single-group, largely preclinical evidence with little independent replication.
• Selank and Semax — Russian-developed nootropic neuropeptides studied for anxiety/cognition. Like Pinealon, their human evidence is concentrated in Russian-language literature and is not established by independent, modern, registered trials.

Common misconceptions

• "Pinealon is a proven nootropic that improves human memory." Not established. The human reports are limited, older, single-group, largely Russian-language, and unreplicated [Human]; there are no well-established independent clinical trials.
• "It's clinically shown to protect neurons and reverse Alzheimer's changes." The neuroprotection, dendritic-spine and maze-learning findings are in cells and rodent disease models [In vitro/Animal], not proof of a clinical effect in people.
• "A tiny peptide obviously can't reach the nucleus and change gene expression." The originating group reports exactly that in vitro [In vitro/Hypothesis] — but reporting it in cell systems is not the same as establishing it as the physiological mechanism in humans.
• "It survives digestion, so oral dosing works." Oral-bioavailability claims come from secondary/marketing sources and were not verified from any primary pharmacokinetic study.
• "It's WADA-banned under S0." No primary WADA source lists Pinealon. That claim is inference from its unapproved status, not a WADA assertion.